Neurology Today

​​​​​​​​​​Congress of the European Committee for Treatment and Research in Multiple Sclerosis

The Neurology Today Conference Reporter aims to keep neurologists up to date and fully informed about the most noteworthy news from major professional meetings.  
 
Whether you are attending the meeting or reading about it remotely, you’ll be able to access daily, concise peer-reviewed reports from major neurology conferences via email blasts that are optimized for web and mobile viewing.
 
The Neurology Today Conference Reporter highlights only those papers and presentations deemed noteworthy by the Neurology Today editors. All reports are vetted and reviewed by our team of neurologist reviewers, as well. Each report includes commentary from independent experts and appears with additional perspectives in the print edition of Neurology Today.​​

Peer-reviewed by the Neurology Today Editors

Ringel, Steve USENEW.jpg Avitzur_OrlyNEW.jpg Holloway_RobertNEW.jpg Tyler_KenNEW.jpg Corboy_JohnNEW.jpg
From left to right: Editor-in-Chief Steven P. Ringel, MD, FAAN, professor and director of the neuromuscular division, University of Colorado School of Medicine; Associate Editor Orly Avitzur, MD, FAAN, clinical assistant professor of neurology, New York Medical College; Associate Editor Robert G. Holloway Jr., MD, MPH, FAAN, professor and chair of neurology, University of Rochester Medical Center; Associate Editor Kenneth L. Tyler, MD, FAAN, Reuler-Lewin family professor and chair of neurology, University of Colorado; Advisory Trustee John R. Corboy, MD, FAAN, professor of neurology, co-director of the Rocky Mountain Multiple Sclerosis Center at Anschutz Medical Campus, University of Colorado.​

Hot off the press from the 2016 Congress of the European Committee for Treatment and Research in Multiple Sclerosis:​

September 17—Siponimod Appears to Slow Progression of Advanced MS, Study Finds

September 17—Study Finds Hints of Efficacy of Fluoxetine Among Advanced MS Patients

September 16—Opicinumab Fails to Reverse Disability in Advanced MS

September 16—Neurofilament Blood Test May Detect MS Progression

September 16—Lipoic Acid Therapy Found to Slow Rate of Brain Atrophy

September 15—Intense Exercise Found Not to Help Fatigue in MS

September 15—Meta-Analysis Shows Stem Cell Transplantation Halts MS Progression for At Least Five Years​​


Reports from the 2015 Congress of the European Committee for Treatment and Research in Multiple Sclerosis:

October 12—In Third Trial, Ocrelizumab Shows Promise in Progressive MS

Read expanded coverage here.

October 12—Natalizumab Versus Fingolimod: Dueling Studies, Conflicting Results

October 10—Reports of Dramatic Results of Ocrelizumab for Relapsing-Remitting MS

Read expanded coverage here.

October 10—Alemtuzumab Reported to Keep MS Patients Relapse-Free Three Years After Last Treatment

October 9—Stopping Treatment in Stable MS Patients Linked to Progressive Disease

October 9—Extended Natalizumab Dosing Found Not to Increase the Risk of Relapse in Relapsing-Remitting MS

Read expanded coverage here.

October 9—Pregnancy Does Not Prove Neuroprotective for Women with MS Who Stop Taking Natalizumab

Read expanded coverage here.

 

Congress of ECTRIMS
Fay.Ellis
Access daily, concise peer-reviewed reports from the Congress of ECTRIMS selected by the Neurology Today editors.

Latest Entry: 9/18/2016 Opicinumab Fails to Reverse Disability in Advanced MS Patients